Jin Hyoung Kang
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases (NCT05477615) | Jin Hyoung Kang | 2022-08-01 |
| Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. (NCT05326425) | Jin Hyoung Kang | 2021-06-23 |
Track Jin Hyoung Kang automatically
Every clearance here is in the API, with alerts when new ones post.